Site Editor
Sandy Srinivas, MD
Sandy Srinivas, MD
Posted: Monday, October 3, 2022
According to updated results and biomarker analysis from the phase III PROpel trial, presented at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract 1357O), a combination treatment of abiraterone and olaparib may result in durable survival benefits for some patients with metastatic castration-resistant prostate cancer. Initial study results indicated an association between the dual treatment and improved radiographic progression–free survival.
“Updated results show a continuing trend toward improved [overall survival] and support a superior clinical benefit with [abiraterone plus olaparib versus abiraterone plus placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer],” concluded Fred Saad, MD, of the University of Montreal, and colleagues.
The double-blind study included 796 patients who were randomly assigned to receive either 300 mg of olaparib twice daily or placebo. All patients received 1,000 mg of abiraterone daily plus 5 mg of prednisone or prednisolone twice daily. Radiographic progression–free survival was longer with abiraterone plus olaparib irrespective of biomarker subgroup. Biomarker subgroups included homologous recombination repair gene mutation, nonhomologous recombination repair gene mutation, and breast cancer gene status. Patients with homologous recombination repair gene mutations were distributed evenly across treatment arms.
The initial data cutoff was July 2021; the data cutoff for the interim analysis was March 2022. At the second data cutoff, radiographic progression–free survival remained longer with abiraterone plus olaparib (25 months) versus abiraterone plus placebo (16.4 months). Overall survival trended longer with abiraterone plus olaparib, at 40% maturity at the time of the interim analysis. No change was reported in safety or tolerability results.
Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.
JNCCN Spotlights
Resources
For your Patients
